您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Sodium taurodeoxycholate hydrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sodium taurodeoxycholate hydrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Sodium taurodeoxycholate hydrate图片
CAS NO:207737-97-1
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品名称
牛磺脱氧胆酸钠水合物
产品介绍
Sodium taurodeoxycholate hydrate 是一种胆汁酸,是由肝脏中的胆固醇合成的两亲性表面活性剂分子。 除TGR5通路外,Sodium taurodeoxycholate hydrate 还激活S1PR2通路。
生物活性

Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized fromcholesterolin the liver. Sodium taurodeoxycholate hydrate activates theS1PR2pathway in addition to theTGR5pathway[1].

IC50& Target

Microbial Metabolite

 

体外研究
(In Vitro)

The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals[1].
Taurodeoxycholate inhibits the binding of N-3H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC50of 170 μM[1].
Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation[2].
Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells[2].

Cell Proliferation Assay[2]

Cell Line:IEC-6 and caco-2 cells
Concentration:0, 0.05, 0.50, and 1.00 mM
Incubation Time:1, 2, 4 and 6 days
Result:Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner.

Cell Cycle Analysis[2]

Cell Line:IEC-6 cells
Concentration:0, 0.05, 0.50, and 1.00 mM
Incubation Time:24 h
Result:Significantly increased cells in S phase and decreased cells in G1-phase.

Western Blot Analysis[2]

Cell Line:IEC-6 cells
Concentration:0.5 mM
Incubation Time:1 and 6 days
Result:Significantly increased c-myc protein expression.
体内研究
(In Vivo)

Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[1].

Animal Model:C57BL/6N mice,Lipopolysaccharides(HY-D1056) injection model of sepsis[1]
Dosage:0.5 mg/kg
Administration:Intravenous injection, 30 min or 24 h after LPS injection
Result:Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.
分子量

521.69

性状

Solid

Formula

C26H44NNaO6S

CAS 号

207737-97-1

中文名称

牛磺脱氧胆酸钠水合物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month